TANGO THERAPEUTICS INC (TNGX)
Health Care · Precision oncology / biomarker-driven therapeutics · NASDAQ
An early-stage precision oncology company developing biomarker-driven cancer therapeutics for genetically defined patient populations.
What TANGO THERAPEUTICS INC does
Tango Therapeutics is a precision oncology company focused on discovering and developing therapeutics for patients with genetically defined or biomarker-driven cancers. The company has no products approved for commercial sale and has never generated revenue from product sales. Its approach combines novel target discovery with companion diagnostic and biomarker screening to enable patient selection for clinical trials, though the company is still in preclinical and early clinical development stages.
Themes: ["Precision oncology","Biomarker-driven therapeutics","Genetically defined cancers","Companion diagnostics"]
Fundamentals
- Price$30.52 as of 2026-07-09 close
- Market cap$5.0B as of 2026-07-10
- 1-year return+437.5% as of 2026-07-09 close
- Net margin-151.2% as of 2026-07-10
- ROE-41.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+39.0% as of 2026-07-10
- Revenue CAGR (3y)+35.9% SEC XBRL
- Beta1.12 as of 2026-07-10
Key risks (from latest filing)
["No approved products and no product revenue; company has never completed any clinical trials and may never successfully develop marketable products","Substantial funding requirements with continued net losses anticipated; inability to raise capital could force delay or elimination of development programs","Clinical development is lengthy and expensive with uncertain outcomes; potential for significant adverse events during trials that could prevent regulatory approval"]
Competitors & peers
- Guardant Health
- Exact Sciences
- Foundation Medicine
- Tempus AI
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.